| Name | Title | Contact Details |
|---|
The "Technology Innovation Studio (TINS)" is a physical space at the Cambridge Innovation Center (CIC) in Kendall Square that brings together business leaders, scientists and researchers, serial entrepreneurs, angel/VC investors, industry experts, corporate innovation teams and also policy experts to explore and apply tools, methods and models in innovation.
At Flow, AI isnt just a feature—its the core of everything we do. We are transforming the wholesale insurance industry by building a futuristic insurance brokerage where AI powers every aspect of the experience. With advanced AI features already live in production and actively used by our brokers, we are pioneering Wholesale 3.0, equipping brokers with cutting-edge tools to provide unparalleled service. We are creating an ecosystem of AI agents designed to streamline processes and enhance decision-making in the insurance landscape. The industry relies heavily on text—emails, files, and documents—making Generative AI a perfect fit for solving its challenges. Flow leverages AI to deliver meaningful insights, deep analysis, and white-glove support for every transaction, no matter the deal size. By combining human expertise with Platformless AI, we are bringing back the art of wholesale insurance while eliminating the need for outdated portals. In the past seven months, weve grown 250% month-over-month(!) and are forecasting even more massive growth. Were a Series A startup with over $20M raised from top investors like Lightspeed, MunichRe Ventures, and industry angels.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
From the food you eat to the fuels you require, CPM plays an important role in building a more efficient and sustainable world. Our experienced team and family of trusted brands are working together to make our planet a better place to live. Feed Solutions: Were innovating nutrition for both people and animals. Our processes and equipment extract oils and plant-based proteins and create ground and pelleted feed for livestock. Fuel Solutions: Our extensive experience in processing agricultural material has made us a leader in renewable fuel production. We help our customers create renewable diesel, ethanol, sustainable aviation fuel, biogas and energy storage technologies, and our machines create wood pellets, firelogs and briquettes that provide sustainable, renewable cleaner-burning fuels. Build Solutions: From the extrusion machines that help create parts for mobility markets to processes that solve complex recycling challenges to equipment that promotes the use of sustainable aluminum packaging, we contribute the materials and processes to build a better world.
Since 2000, INSBANK has offered its clients highly personalized service provided by experienced relationship managers, while positioning itself as an innovator, utilizing technologies to deliver those services efficiently and conveniently. In addition to its commercial focused operation, INSBANK operates three divisions, Medquity, TMA Medical Banking and INSBANK Online. Medquity offers healthcare banking solutions nationwide to healthcare companies and to individuals, whether they are still in residency, practicing or entering retirement, while TMA Medical Banking provides banking services specifically to members of the Tennessee Medical Association. INSBANK Online offers nationally available virtual private client services for interest bearing deposits. INSBANK is owned by InsCorp, Inc., a Tennessee bank holding company, traded on the OTCQX under symbol IBTN.